Artificial intelligence is moving rapidly into healthcare. From clinical decision support to mental health chatbots, AI tools are increasingly positioned as efficiency multipliers and clinical enhancers.
But speed is not the same as readiness.
A recent discussion in the Harvard Gazette featuring Harvard Law professor I. Glenn Cohen raises a fundamental question: who should regulate AI in healthcare, and how do we prevent harm while enabling innovation?
For treatment center leadership, this is not theoretical. AI tools are already being marketed for intake screening, clinical documentation, utilization review, relapse prediction, and admissions optimization.
The question is no longer whether AI will enter addiction treatment.
The question is whether facilities will adopt it responsibly.
AI systems can generate recommendations for clinicians. They can analyze patterns across thousands of cases. They can summarize notes, flag risk indicators, and assist in care planning.
But they can also produce inaccurate outputs, what technologists call “hallucinations.” In a consumer context, this may be inconvenient. In healthcare, it can be harmful.
If an AI model misclassifies a client’s risk level, misinterprets symptom data, or embeds biased patterns into recommendations, the downstream effects are operational and ethical. Treatment decisions may shift. Documentation may reflect inaccuracies. Clinical teams may over-rely on automated outputs.
Addiction treatment already operates in a high-risk, high-regulation environment. Introducing AI without governance amplifies liability exposure.
This is not about rejecting innovation. It is about aligning adoption with accountability.
The Core Regulatory Dilemma
Healthcare AI currently exists in a fragmented oversight environment. Most AI systems used in hospitals are not directly reviewed by federal regulators. Instead, oversight is largely internal, conducted facility by facility.
That creates two problems.
First, internal validation is expensive. Large hospital systems may spend between $300,000 and $500,000 to properly vet and monitor a complex algorithm. Smaller systems often cannot absorb that cost.
Second, implementation varies. The same AI tool may perform differently depending on staffing models, clinical training, workflow design, and resource levels. Unlike a drug, whose biochemical effects are relatively stable, AI performance depends heavily on how it is deployed.
For treatment centers, many of which are mid-sized or small facilities, this raises a strategic challenge. If accreditation bodies eventually incorporate AI governance standards into compliance requirements, adoption may require multidisciplinary committees, continuous quality monitoring, bias audits, and formal consent disclosures.
That is infrastructure, not software.
Ethical Safeguards: What Responsible Adoption Requires
Recent guidelines from the Joint Commission and the Coalition for Health AI suggest that when AI directly impacts patient care, disclosure should occur and, in some cases, informed consent should be obtained. They also recommend continuous monitoring of accuracy, adverse events, and equity across populations.
If taken seriously, these recommendations impose ongoing operational responsibilities.
Treatment centers considering AI implementation should evaluate:
- How will the model be validated before deployment?
- Who monitors performance over time?
- How are errors detected and corrected?
- Are clients informed when AI influences their care?
- How is bias assessed across demographics?
These are governance questions.
AI adoption without governance exposes facilities to regulatory scrutiny and reputational risk.
The Equity and Access Question
There is also a structural concern.
If only large, well-capitalized health systems can afford the cost of validating and monitoring AI tools, smaller facilities may be excluded from access. That could widen disparities in care quality and operational efficiency.
At the same time, many AI tools are trained on national datasets that include clients from smaller and rural facilities. If those communities contribute data but cannot access the benefits due to compliance burdens, inequities deepen.
For addiction treatment, where rural and underserved communities already face access challenges, this is not an abstract policy debate. It is a distributional issue.
Leadership teams must consider not just operational feasibility, but fairness and long-term positioning.
Faebl Executive Perspective
AI in addiction treatment should not be approached as a marketing enhancement or cost-cutting shortcut.
It is a clinical infrastructure.
Before implementing AI tools for admissions scoring, documentation automation, or predictive relapse analytics, facilities should establish clear governance frameworks. That includes cross-functional oversight between clinical leadership, operations, and compliance teams.
Adoption should follow a structured process:
- Strategic clarity on use case
- Risk classification based on impact to client care
- Formal validation prior to deployment
- Ongoing monitoring with defined performance metrics
- Transparent communication policies
AI will improve efficiency across the industry. But facilities that adopt prematurely, without operational safeguards, risk regulatory exposure and clinical instability.
Responsible adoption builds trust with clients, staff, and regulators.
Final Perspective
Artificial intelligence will meaningfully shape healthcare over the next decade. Even leading ethicists acknowledge its transformative potential.
But innovation does not self-regulate.
In addiction treatment, where decisions directly affect vulnerable populations, ethical oversight is not optional. It is foundational.
The leadership question is not “How fast can we implement AI?”
It is:
Do we have the governance, validation, and monitoring infrastructure necessary to deploy AI responsibly?
Facilities that answer that question deliberately will be positioned to benefit from AI’s capabilities without compromising clinical integrity or regulatory standing.
That is the difference between technological adoption and operational leadership.
